Literature DB >> 18936738

MethyQESD, a robust and fast method for quantitative methylation analyses in HNPCC diagnostics using formalin-fixed and paraffin-embedded tissue samples.

Marcus Bettstetter1, Stefan Dechant, Petra Ruemmele, Corinna Vogel, Katrin Kurz, Monika Morak, Gisela Keller, Elke Holinski-Feder, Ferdinand Hofstaedter, Wolfgang Dietmaier.   

Abstract

Promoter hypermethylation occurs in various tumors and leads to silencing of tumor-relevant genes. Thus, promoter methylation analysis (MA) has been established as an important tool in cancer research and diagnostics. Here we present MethyQESD (methylation-quantification of endonuclease-resistant DNA) as a fast, easy, precise and reliable method for quantitative MA without the need of bisulfite-treatment or fluorescent probes. Though MethyQESD principally works with any gene promoter we established MethyQESD for the mismatch repair gene MLH1 and tested its utility to differentiate between sporadic microsatellite unstable (MSI-H) colorectal cancer and hereditary nonpolyposis colorectal cancer (HNPCC) by quantitative MLH1 MA. We investigated formalin-fixed and paraffin-embedded tissue samples from a previously published, well-characterized tumor collective comprising 25 HNPCC, 14 sporadic MSI-H CRC and 16 sporadic microsatellite stable (MSS) CRC. We found a high accuracy of MethyQESD by spiking experiments with dilution series of methylated (SW48 cancer cell line) and unmethylated (blood) DNA (Pearson's r=0.9997 (proximal MLH1 promoter region), r=0.9976 (distal MLH1 promoter region)). MethyQESD and conventional quantitative MA using of 96 formalin-fixed and paraffin-embedded CRC showed a high degree of concordance of both methods (Pearson's r=0.885). HNPCC tumors showed either null MLH1 methylation or a significantly lower degree of MLH1 methylation than sporadic MSI-H CRC (P<0.001). MLH1 methylation was negative in all MSS tumors. Receiver operating characteristic (ROC) curve analyses defined a cutoff value of 16.5% MLH1 methylation for specific and sensitive identification of sporadic MSI-H CRC (area under ROC curve: 1.000; asymptotic significance: P<0.001). Thus, quantitative MLH1 MA by MethyQESD provides a simple, fast and valuable tool to identify HNPCC candidates. Furthermore, MethyQESD works reliably with formalin-fixed paraffin-embedded tissue and simplifies DNA MA both for research and diagnostic purposes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18936738     DOI: 10.1038/labinvest.2008.100

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  11 in total

1.  [Molecular diagnostics in neuropathology].

Authors:  W Dietmaier; J Lorenz; M J Riemenschneider
Journal:  Pathologe       Date:  2015-03       Impact factor: 1.011

2.  Modern day screening for Lynch syndrome in endometrial cancer: the KEM experience.

Authors:  Nina Pauly; Thaïs Baert; Rita Schmutzler; Andreas du Bois; Stephanie Schneider; Kerstin Rhiem; Birgid Schömig-Markiefka; Janna Siemanowski; Sebastian Heikaus; Alexander Traut; Florian Heitz; Sonia Prader; Sarah Ehmann; Philipp Harter; Beyhan Ataseven
Journal:  Arch Gynecol Obstet       Date:  2021-03-12       Impact factor: 2.344

3.  Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab.

Authors:  Elisabeth Bumes; Sarah Rzonsa; Markus Hutterer; Martin Proescholdt; Ulrich Bogdahn; Markus J Riemenschneider; Martin Uhl; Christina Wendl; Peter Hau
Journal:  J Neurooncol       Date:  2015-12-31       Impact factor: 4.130

4.  Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas.

Authors:  Moritz Jesinghaus; Björn Konukiewitz; Gisela Keller; Matthias Kloor; Katja Steiger; Magdalena Reiche; Roland Penzel; Volker Endris; Ruza Arsenic; Gratiana Hermann; Albrecht Stenzinger; Wilko Weichert; Nicole Pfarr; Günter Klöppel
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

5.  Quantitative detection of TUSC3 promoter methylation -a potential biomarker for prognosis in lung cancer.

Authors:  Uta Duppel; Matthias Woenckhaus; Christian Schulz; Johannes Merk; Wolfgang Dietmaier
Journal:  Oncol Lett       Date:  2016-08-01       Impact factor: 2.967

Review 6.  [Hereditary colon cancer in Lynch syndrome/HNPCC syndrome in Germany].

Authors:  R Büttner; N Friedrichs
Journal:  Pathologe       Date:  2019-11       Impact factor: 1.011

7.  A randomized, double-blind, placebo-controlled, clinical trial on probiotic soy milk and soy milk: effects on epigenetics and oxidative stress in patients with type II diabetes.

Authors:  Mitra Hariri; Rasoul Salehi; Awat Feizi; Maryam Mirlohi; Reza Ghiasvand; Nahal Habibi
Journal:  Genes Nutr       Date:  2015-11-17       Impact factor: 5.523

8.  BRAF mutation in sporadic colorectal cancer and Lynch syndrome.

Authors:  Alexandra Thiel; Mira Heinonen; Jonas Kantonen; Annette Gylling; Laura Lahtinen; Mari Korhonen; Soili Kytölä; Jukka-Pekka Mecklin; Arto Orpana; Päivi Peltomäki; Ari Ristimäki
Journal:  Virchows Arch       Date:  2013-08-21       Impact factor: 4.064

9.  Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma.

Authors:  Andrea Schäfer; Julian Teufel; Florian Ringel; Marcus Bettstetter; Ingrid Hoepner; Michael Rasper; Jens Gempt; Julia Koeritzer; Friederike Schmidt-Graf; Bernhard Meyer; Christoph P Beier; Jürgen Schlegel
Journal:  Neuro Oncol       Date:  2012-11-06       Impact factor: 12.300

10.  Cytosolic Hsp70 as a biomarker to predict clinical outcome in patients with glioblastoma.

Authors:  Friederike Lämmer; Claire Delbridge; Silvia Würstle; Frauke Neff; Bernhard Meyer; Jürgen Schlegel; Kerstin A Kessel; Thomas E Schmid; Daniela Schilling; Stephanie E Combs
Journal:  PLoS One       Date:  2019-08-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.